AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. SSP
  4. [8-K] The E.W. Scripps Company Reports Material Event

[8-K] The E.W. Scripps Company Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Artiva Biotherapeutics (ARTV) filed a Form 8-K on August 6, 2025. Under Item 2.02, the company disclosed that it issued a press release announcing financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is expressly not deemed 鈥渇iled鈥� for liability purposes under Section 18 of the Exchange Act. Item 9.01 lists the exhibits included in the filing, namely the press release and the cover-page Inline XBRL data file. No actual financial figures, guidance, or narrative commentary are contained within the 8-K itself.

The filing is procedural, serving mainly to make the earnings release publicly available while limiting legal exposure. Investors must review Exhibit 99.1 for quantitative details.

Artiva Biotherapeutics (ARTV) ha presentato un Modulo 8-K il 6 agosto 2025. Ai sensi del Punto 2.02, la societ脿 ha comunicato di aver diffuso un comunicato stampa con i risultati finanziari del trimestre terminato il 30 giugno 2025. Il comunicato 猫 allegato come Exhibit 99.1 e non 猫 considerato formalmente depositato ai fini di responsabilit脿 secondo la Sezione 18 del Exchange Act. Il Punto 9.01 elenca gli allegati inclusi nella presentazione, ovvero il comunicato stampa e il file dati Inline XBRL della pagina di copertina. Nel modulo 8-K non sono presenti dati finanziari concreti, previsioni o commenti narrativi.

La presentazione ha carattere procedurale, servendo principalmente a rendere pubblico il comunicato sugli utili limitando l鈥檈sposizione legale. Gli investitori devono consultare l鈥橢xhibit 99.1 per i dettagli quantitativi.

Artiva Biotherapeutics (ARTV) present贸 un Formulario 8-K el 6 de agosto de 2025. Bajo el Punto 2.02, la compa帽铆a revel贸 que emiti贸 un comunicado de prensa anunciando los resultados financieros del trimestre finalizado el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y no se considera formalmente presentado para fines de responsabilidad seg煤n la Secci贸n 18 de la Ley de Intercambio. El Punto 9.01 enumera los anexos incluidos en la presentaci贸n, que son el comunicado de prensa y el archivo de datos Inline XBRL de la portada. El 8-K en s铆 no contiene cifras financieras reales, pron贸sticos ni comentarios narrativos.

La presentaci贸n es de car谩cter procedimental, sirviendo principalmente para hacer p煤blico el comunicado de resultados mientras limita la exposici贸n legal. Los inversores deben revisar el Exhibit 99.1 para obtener detalles cuantitativos.

Artiva Biotherapeutics (ARTV)電� 2025雲� 8鞗� 6鞚检棎 Form 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 頃 2.02鞐� 霐半澕 須岇偓電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴 鞛 瓴瓣臣毳� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚滍枆頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟. 氤措弰鞛愲電� Exhibit 99.1搿� 觳秬霅橃棃鞙茧┌, Exchange Act 靹轨厴 18鞐� 霐半ジ 氩曥爜 毂呾瀯 氇╈爜靸� 鞝曥嫕 鞝滌稖霅� 瓴冹溂搿� 臧勳＜霅橃 鞎婌姷雼堧嫟. 頃 9.01鞐愲姅 鞝滌稖 靹滊鞐� 韽暔霅� 鞝勳嫓氍�, 歃� 氤措弰鞛愲鞕� 響滌 韼橃澊歆�鞚� Inline XBRL 雿办澊韯� 韺岇澕鞚� 雮橃棿霅橃柎 鞛堨姷雼堧嫟. 8-K 鞛愳泊鞐愲姅 鞁れ牅 鞛 靾橃箻, 鞝勲 霕愲姅 靹滌垹鞝� 頃挫劋鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.

鞚措矆 鞝滌稖鞚� 鞝堨皑鞝� 靹标博鞙茧, 欤茧 鞁れ爜 氚滍憸毳� 瓿店皽頃橂姅 霃欖嫓鞐� 氩曥爜 雲胳稖鞚� 鞝滍暅頃橂姅 氇╈爜鞛呺媹雼�. 韴瀽鞛愲姅 鞝曤焿鞝� 靹鸽秬靷暛鞚� 頇曥澑頃橁赴 鞙勴暣 Exhibit 99.1鞚� 瓴�韱犿暣鞎� 頃╇媹雼�.

Artiva Biotherapeutics (ARTV) a d茅pos茅 un formulaire 8-K le 6 ao没t 2025. Selon l鈥橝rticle 2.02, la soci茅t茅 a annonc茅 la publication d鈥檜n communiqu茅 de presse pr茅sentant les r茅sultats financiers du trimestre clos au 30 juin 2025. Le communiqu茅 est fourni en tant qu鈥橢xhibit 99.1 et n鈥檈st express茅ment pas consid茅r茅 comme 芦 d茅pos茅 禄 aux fins de responsabilit茅 en vertu de la Section 18 du Exchange Act. L鈥橝rticle 9.01 茅num猫re les annexes incluses dans le d茅p么t, 脿 savoir le communiqu茅 de presse et le fichier de donn茅es Inline XBRL de la page de couverture. Le formulaire 8-K lui-m锚me ne contient aucun chiffre financier r茅el, aucune pr茅vision ni commentaire narratif.

Le d茅p么t est de nature proc茅durale, visant principalement 脿 rendre public le communiqu茅 sur les r茅sultats tout en limitant l鈥檈xposition juridique. Les investisseurs doivent consulter l鈥橢xhibit 99.1 pour les d茅tails quantitatifs.

Artiva Biotherapeutics (ARTV) reichte am 6. August 2025 ein Formular 8-K ein. Unter Punkt 2.02 gab das Unternehmen bekannt, dass es eine Pressemitteilung mit den Finanzergebnissen f眉r das Quartal zum 30. Juni 2025 ver枚ffentlicht hat. Die Pressemitteilung ist als Exhibit 99.1 beigef眉gt und wird ausdr眉cklich nicht als 鈥瀍ingereicht鈥� im Sinne der Haftung gem盲脽 Abschnitt 18 des Exchange Act betrachtet. Punkt 9.01 listet die im Einreichungsdokument enthaltenen Anlagen auf, n盲mlich die Pressemitteilung und die Inline-XBRL-Datendatei der Titelseite. Das 8-K enth盲lt selbst keine tats盲chlichen Finanzzahlen, Prognosen oder erl盲uternde Kommentare.

Die Einreichung ist prozedural und dient haupts盲chlich dazu, die Gewinnver枚ffentlichung 枚ffentlich zug盲nglich zu machen und gleichzeitig die rechtliche Haftung zu begrenzen. Investoren m眉ssen Exhibit 99.1 f眉r quantitative Details pr眉fen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine 8-K furnishes Q2-25 earnings release; no numbers disclosed here.

The 8-K is purely administrative, triggering no immediate valuation insight because it omits the underlying financial metrics. Management uses Item 2.02 to ensure Reg FD compliance while keeping the furnished material outside Section 18 liability. Impact on the stock will depend entirely on the content of Exhibit 99.1, which is not provided. Therefore, the filing itself is neutral and non-impactful from an analytical standpoint.

Artiva Biotherapeutics (ARTV) ha presentato un Modulo 8-K il 6 agosto 2025. Ai sensi del Punto 2.02, la societ脿 ha comunicato di aver diffuso un comunicato stampa con i risultati finanziari del trimestre terminato il 30 giugno 2025. Il comunicato 猫 allegato come Exhibit 99.1 e non 猫 considerato formalmente depositato ai fini di responsabilit脿 secondo la Sezione 18 del Exchange Act. Il Punto 9.01 elenca gli allegati inclusi nella presentazione, ovvero il comunicato stampa e il file dati Inline XBRL della pagina di copertina. Nel modulo 8-K non sono presenti dati finanziari concreti, previsioni o commenti narrativi.

La presentazione ha carattere procedurale, servendo principalmente a rendere pubblico il comunicato sugli utili limitando l鈥檈sposizione legale. Gli investitori devono consultare l鈥橢xhibit 99.1 per i dettagli quantitativi.

Artiva Biotherapeutics (ARTV) present贸 un Formulario 8-K el 6 de agosto de 2025. Bajo el Punto 2.02, la compa帽铆a revel贸 que emiti贸 un comunicado de prensa anunciando los resultados financieros del trimestre finalizado el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y no se considera formalmente presentado para fines de responsabilidad seg煤n la Secci贸n 18 de la Ley de Intercambio. El Punto 9.01 enumera los anexos incluidos en la presentaci贸n, que son el comunicado de prensa y el archivo de datos Inline XBRL de la portada. El 8-K en s铆 no contiene cifras financieras reales, pron贸sticos ni comentarios narrativos.

La presentaci贸n es de car谩cter procedimental, sirviendo principalmente para hacer p煤blico el comunicado de resultados mientras limita la exposici贸n legal. Los inversores deben revisar el Exhibit 99.1 para obtener detalles cuantitativos.

Artiva Biotherapeutics (ARTV)電� 2025雲� 8鞗� 6鞚检棎 Form 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 頃 2.02鞐� 霐半澕 須岇偓電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴 鞛 瓴瓣臣毳� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚滍枆頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟. 氤措弰鞛愲電� Exhibit 99.1搿� 觳秬霅橃棃鞙茧┌, Exchange Act 靹轨厴 18鞐� 霐半ジ 氩曥爜 毂呾瀯 氇╈爜靸� 鞝曥嫕 鞝滌稖霅� 瓴冹溂搿� 臧勳＜霅橃 鞎婌姷雼堧嫟. 頃 9.01鞐愲姅 鞝滌稖 靹滊鞐� 韽暔霅� 鞝勳嫓氍�, 歃� 氤措弰鞛愲鞕� 響滌 韼橃澊歆�鞚� Inline XBRL 雿办澊韯� 韺岇澕鞚� 雮橃棿霅橃柎 鞛堨姷雼堧嫟. 8-K 鞛愳泊鞐愲姅 鞁れ牅 鞛 靾橃箻, 鞝勲 霕愲姅 靹滌垹鞝� 頃挫劋鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.

鞚措矆 鞝滌稖鞚� 鞝堨皑鞝� 靹标博鞙茧, 欤茧 鞁れ爜 氚滍憸毳� 瓿店皽頃橂姅 霃欖嫓鞐� 氩曥爜 雲胳稖鞚� 鞝滍暅頃橂姅 氇╈爜鞛呺媹雼�. 韴瀽鞛愲姅 鞝曤焿鞝� 靹鸽秬靷暛鞚� 頇曥澑頃橁赴 鞙勴暣 Exhibit 99.1鞚� 瓴�韱犿暣鞎� 頃╇媹雼�.

Artiva Biotherapeutics (ARTV) a d茅pos茅 un formulaire 8-K le 6 ao没t 2025. Selon l鈥橝rticle 2.02, la soci茅t茅 a annonc茅 la publication d鈥檜n communiqu茅 de presse pr茅sentant les r茅sultats financiers du trimestre clos au 30 juin 2025. Le communiqu茅 est fourni en tant qu鈥橢xhibit 99.1 et n鈥檈st express茅ment pas consid茅r茅 comme 芦 d茅pos茅 禄 aux fins de responsabilit茅 en vertu de la Section 18 du Exchange Act. L鈥橝rticle 9.01 茅num猫re les annexes incluses dans le d茅p么t, 脿 savoir le communiqu茅 de presse et le fichier de donn茅es Inline XBRL de la page de couverture. Le formulaire 8-K lui-m锚me ne contient aucun chiffre financier r茅el, aucune pr茅vision ni commentaire narratif.

Le d茅p么t est de nature proc茅durale, visant principalement 脿 rendre public le communiqu茅 sur les r茅sultats tout en limitant l鈥檈xposition juridique. Les investisseurs doivent consulter l鈥橢xhibit 99.1 pour les d茅tails quantitatifs.

Artiva Biotherapeutics (ARTV) reichte am 6. August 2025 ein Formular 8-K ein. Unter Punkt 2.02 gab das Unternehmen bekannt, dass es eine Pressemitteilung mit den Finanzergebnissen f眉r das Quartal zum 30. Juni 2025 ver枚ffentlicht hat. Die Pressemitteilung ist als Exhibit 99.1 beigef眉gt und wird ausdr眉cklich nicht als 鈥瀍ingereicht鈥� im Sinne der Haftung gem盲脽 Abschnitt 18 des Exchange Act betrachtet. Punkt 9.01 listet die im Einreichungsdokument enthaltenen Anlagen auf, n盲mlich die Pressemitteilung und die Inline-XBRL-Datendatei der Titelseite. Das 8-K enth盲lt selbst keine tats盲chlichen Finanzzahlen, Prognosen oder erl盲uternde Kommentare.

Die Einreichung ist prozedural und dient haupts盲chlich dazu, die Gewinnver枚ffentlichung 枚ffentlich zug盲nglich zu machen und gleichzeitig die rechtliche Haftung zu begrenzen. Investoren m眉ssen Exhibit 99.1 f眉r quantitative Details pr眉fen.

false000083242800008324282025-08-062025-08-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 6, 2025
THE E.W. SCRIPPS COMPANY
(Exact name of registrant as specified in its charter)
 
Ohio 001-10701 31-1223339
(State or other jurisdiction of
incorporation)		 (Commission
File Number)		 (I.R.S. Employer
Identification Number)
 
312 Walnut Street
Cincinnati,Ohio45202
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (513) 977-3000
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act.
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A Common Stock, par value $0.01 per shareSSPNASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



THE E.W. SCRIPPS COMPANY
INDEX TO CURRENT REPORT ON FORM 8-K
 
Item No.Page
1.01Entry Into a Material Definitive Agreement3
2.03Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant4
8.01Other Events4
9.01Financial Statements and Exhibits4

2

Item 1.01 Entry Into a Material Definitive Agreement

On August 6, 2025, The E.W. Scripps Company (the “Company”), the subsidiary guarantors named therein (the “Guarantors”) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”) and collateral agent (the “Collateral Agent”), entered into an indenture (the “Indenture”), pursuant to which the Company issued $750,000,000 aggregate principal amount of new 9.875% senior secured second lien notes due 2030 (the “Notes”).

The Notes will mature on August 15, 2030, and interest on the Notes is payable semi-annually in arrears on each August 15 and February 15, commencing February 15, 2026, to holders of record on the August 1 and February 1 immediately preceding the related interest payment date, at a rate of 9.875% per annum.

The Notes are guaranteed on a senior secured second lien basis by substantially all of the Company’s domestic subsidiaries and each existing and future material, wholly-owned domestic subsidiary, subject to certain exceptions (including with respect to permitted securitization facility related entities). The Notes and the related guarantees are secured by a second priority lien on substantially all of the assets of the Company and the Guarantors, subject to permitted liens and certain other exceptions (including with respect to accounts receivables and related assets included in a permitted securitization facility) (the “Collateral”).

The Company may redeem up to 40% of the Notes at 109.875% at any time and from time to time prior to August 15, 2027 with an amount not to exceed the net cash proceeds from certain equity offerings; provided at least 50% of the aggregate principal amount of the Notes originally issued on the issue date remains outstanding immediately after any such redemption (unless all Notes are redeemed or repurchased substantially concurrently). At any time and from time to time prior to August 15, 2027, the Company may redeem all or part of the Notes by paying 100% of the principal amount thereof plus a make whole premium as of, and accrued but unpaid interest, if any, to, the date of such redemption. At any time and from time to time on or after August 15, 2027, the Company may redeem the Notes at its option, in whole or in part, at the redemption prices (expressed as a percentage of the principal amount of the Notes) set forth in the Indenture, plus accrued and unpaid interest to the date of such redemption. If a Change of Control (as defined in the Indenture) occurs, the Company will make an offer to each holder of the Notes to repurchase all or any part of that holder’s Notes for cash at a price equal to 101.0% of the aggregate principal amount of the Notes repurchased, plus accrued and unpaid interest, if any, on the Notes repurchased to, but excluding, the date of purchase.

The Indenture contains covenants that, among other things and subject to certain exceptions, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) incur certain additional debt, (ii) incur certain liens securing debt, (iii) pay certain dividends or make other restricted payments, (iv) make certain investments, (v) make certain asset sales and (vi) enter into certain transactions with affiliates. The Indenture contains customary events of default, including, among other things, failure to make required payments, failure to comply with certain agreements or covenants, failure to pay or acceleration of certain other indebtedness, certain events of bankruptcy and insolvency, and failure to pay certain judgments. An event of default under the Indenture will allow either the Trustee or the holders of at least 30% in aggregate principal amount of the then-outstanding Notes to accelerate the amounts due under the Notes.

In connection with the issuance of the Notes, on August 6, 2025, the Company, the other grantors named therein, JPMorgan Chase Bank, N.A., as the administrative agent under the Company’s senior credit facilities, U.S. Bank Trust Company, National Association, as the collateral agent under the indenture governing the Company’s 3.875% senior secured notes due 2029, and the Collateral Agent entered into a junior lien intercreditor agreement (the “Junior Lien Intercreditor Agreement”) providing for the relative priorities of their respective security interests in the Collateral and certain other matters relating to the administration of such security interests. Under the terms of the Junior Lien Intercreditor Agreement, any amounts received by the Collateral Agent or any other secured party in respect of the proceeds of Collateral will be applied to repay the holders of first lien debt (which does not include the Notes) prior to any payment in respect of the Collateral to the holders of the Notes and any other indebtedness of the Issuer and the guarantors that does not constitute first lien debt until such obligations are paid in full.

The foregoing description of the Indenture does not purport to be complete and is qualified in its entirety by reference to the full text of the Indenture and the form of 9.875% senior secured second lien note due 2030, which are filed as Exhibit 4.01 and Exhibit 4.02, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.




3

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 8.01 Other Events

On August 6, 2025, the Company redeemed all $426 million aggregate principal amount of its 5.875% Senior Notes due 2027 then outstanding at a redemption price equal to 100.00% of the principal amount outstanding, plus accrued and unpaid interest to, but excluding, the redemption date. Concurrently, the Company pre-paid $205 million aggregate principal amount of its term loan B-2 facility which matures in 2028 at a price equal to 102.000% of the principal amount outstanding, plus accrued and unpaid interest to, but excluding the prepayment date as well as a portion of its revolving credit facilities.

Item 9.01 Financial Statements and Exhibits
Exhibit
Number		Description of Item
4.01
Indenture, dated as of August 6, 2025, by and among The E.W. Scripps Company, the guarantors named therein and U.S. Bank Trust Company, National Association, as trustee and collateral agent
4.02
Form of 9.875% Senior Note due 2030 (included as Exhibit A in Exhibit 4.01)
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

4

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
THE E.W. SCRIPPS COMPANY
BY: /s/ Daniel W. Perschke
 Daniel W. Perschke
 Senior Vice President, Controller
(Principal Accounting Officer)
Dated: August 6, 2025
5

Source:

FAQ

Why did Artiva Biotherapeutics (ARTV) file a Form 8-K on August 6, 2025?

To furnish its press release announcing financial results for the quarter ended June 30, 2025 under Item 2.02.

Does the 8-K include Artiva鈥檚 Q2 2025 financial numbers?

No. The filing references the press release as Exhibit 99.1, but no figures appear in the body of the 8-K.

Is the furnished press release considered "filed" with the SEC?

No. Artiva states the information is not deemed "filed" for purposes of Section 18 of the Exchange Act.

What exhibits accompany the 8-K?

Exhibit 99.1 (press release dated August 6, 2025) and Exhibit 104 (cover-page Inline XBRL data file).

How should investors obtain the actual earnings details?

Investors need to read Exhibit 99.1, which contains the full Q2 2025 financial results.
Stock SSP logo
Scripps E W Co Ohio

NASDAQ:SSP

SSP Rankings

#5468 Ranked by Market Cap
N/A Ranked by Dividends

SSP Latest News

Aug 7, 2025
Scripps reports Q2 2025 financial results
Jul 31, 2025
Scripps taps veteran media strategist to bolster research and consumer insights
Jul 29, 2025
Scripps announces upsize and prices senior notes offering
Jul 28, 2025
Scripps announces proposed placement of senior notes
Jul 10, 2025
Scripps to release second-quarter 2025 operating results on Aug. 7

SSP Latest SEC Filings

Aug 6, 2025
[SCHEDULE 13D/A] The E.W. Scripps Company SEC Filing
Jul 30, 2025
[8-K] The E.W. Scripps Company Reports Material Event
Jul 28, 2025
[8-K] The E.W. Scripps Company Reports Material Event
Jul 7, 2025
[8-K] The E.W. Scripps Company Reports Material Event

SSP Stock Data

263.13M
62.15M
17.97%
72.67%
2.46%
Broadcasting
Television Broadcasting Stations
United States
CININNATI